NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
New Stage III biomarker data in people with ALS validates NeuroSense's clinical strategy, the company reports.
New Stage III biomarker data in people with ALS validates NeuroSense's clinical strategy, the company reports.
ProMIS Neurosciences Inc announces new milestones in potential therapeutic approaches for ALS, the company notes in a media release.
Clene Nanomedicine Inc presents results from Phase 2 RESCUE-ALS and REPAIR trials and preclinical data in ALS at the 2022 MDA Conference.
In a new meta-analysis of available ALS literature, Arizona State University researchers explore environmental influences potentially linked to ALS. The study also examines the distribution of ALS over space and time.
Read MoreAn experimental drug, first tried as a last-ditch effort to help a 25-year-old woman with juvenile ALS, is now being tested in ALS patients in a global, phase 3 clinical trial.
Read MoreComcast and Team Gleason have partnered to drive inclusive innovation to improve the independence and quality of life for people with physical and speech disabilities, including those living with ALS, they report.
Read More“It has become clear that years of repeated impacts to the head can cause the human brain to break down along many pathways,” The Hill reports.
Read MorePresident Joe Biden [recently] signed into law bipartisan legislation that expands funding for amyotrophic lateral sclerosis research, hailing it as in “the spirit of the season,” CNN reports.
Read MoreIsraeli researchers announced [recently] that they have uncovered a key mechanism that causes the neurodegenerative disease ALS, which may unlock a way to delay or reverse the condition which affects thousands of people annually, The Times of Israel reports.
Read MoreA paralyzed man has tweeted a message out to the world using his thoughts through a brain-computer interface, IFL Science reports.
Read MoreThe Alzheimer’s Drug Discovery Foundation and Target ALS announce a new partnership to identify and develop biomarkers for neurodegenerative diseases, including Alzheimer’s disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Degeneration.
Read MoreScientists have determined the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases, they suggest, in Nature.
Read MoreI AM ALS, The ALS Association and the Muscular Dystrophy Association released the following statement on the recent passage of ACT for ALS in the House of Representatives:
Read MoreThe brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists discover, according to research published in Gene Therapy.
Read MoreA new study using genetically engineered mice and human cell and tissue samples has added to evidence that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis (ALS), the neuromuscular disorder also known as Lou Gehrig’s disease.
Read MoreBlocking tau, a hallmark of Alzheimer’s disease, may benefit patients with amyotrophic lateral sclerosis (ALS), researchers suggest.
Read MoreThere is debate over whether vigorous physical activity is a risk factor for amyotrophic lateral sclerosis (ALS). A new study published in Neurology suggests it depends on whether that vigorous activity you get over your lifetime happens on the job or during leisure time.
Read MoreAs part of a new 5-year strategic partnership agreement, Numotion is named Team Gleason’s “Preferred CRT Provider,” it announces.
Read More